Ditemukan 13021 dokumen yang sesuai dengan query :: Simpan CSV
TB problems in Indonesia are TB sensitive, Drug-Resistant TB and TB-HIV. TB-RO is the most challengging problem, the number of case finding is increase every year, but treatment rate is decrease. The use of short-term regiment since September 2017 is one of strategy to reduce default of TB treatment. This research was conducted to see trends and factors related to the TB treatment success rate among patients with Drug Resistance TB (TB RO) using Shorter Treatment Regiment (STR) in Indonesia 2017-2019. The study desain is restropective cohort. Data sources are all patients of TB RO using STR regiment, which is enrolled in the e-TB manager, Sud Directorate of Tuberculosis, MoH RI. The sampling method is total sampling that meets the inclusion and exclusion criteria. The analysis used was the chi-square test and the cox regression test. As many as 3,100 patients were included in the analysis, the treatment success rate was 41,94%. The results of the analysis showed that factors related to treatment success were age, adherence, results of initial sputum examination of treatment, patterns of monoresistant and polyresistant resistance, and area of residence. Adherence is a dominant factor related to treatment success. Efforts should be made to strengthen compliance by conducting counseling as early as possible, PMO assistants from non-helath officers and initiating patient support groups in each MDR facility
Provinsi DKI Jakarta merupakan salah satu dari 4 Provinsi di Indonesia yang menjadi tempat implementasi awal dari penerapan penggunaan paduan BPaL (Bedaquiline, Pretomanid, Linezolid) untuk pengobatan TB RO dalam tatanan penelitian operasional. Tujuan penelitian ini adalah membandingkan keberhasilan pengobatan pasien TB RO pada penggunaan Bedaquiline dalam paduan pengobatan dengan keberhasilan pengobatan pasien TB RO tanpa Bedaquiline dalam paduan pengobatan. Penelitian menggunakan rancangan kohort retrospektif dan analisis datanya dengan analisis survival dari data Sistem Informasi Tuberkulosis (SITB) Provinsi DKI Jakarta tahun 2020 – 2023. Hasil penelitian: Pada pola resistansi Monoresistan, Rifampisin Resistan, Poliresistan dan Multidrugs Resistant keberhasilan paduan pengobatan yang menggunakan Bedaquiline tidak menunjukkan perbedaan yang bermakna dengan keberhasilan pengobatan menggunakan paduan tanpa Bedaquiline setelah dikontrol oleh variabel jenis paduan pengobatan (HR 1,01; 95% CI 0,79 -1,29; p-value= 0,939). Pada pola resistansi pre-Extensively Drug Resistant dan Extensively Drug Resistant, keberhasilan paduan pengobatan menggunakan Bedaquiline juga tidak berbeda bermakna bila dibandingkan keberhasilan paduan pengobatan tanpa Bedaquiline dengan mempertimbangkan jenis paduan pengobatan (HR 1,14; 95% CI 0,34 – 3,82; p-value= 0,835). Diharapkan tenaga kesehatan tetap memberikan edukasi pentingnya kepatuhan regimen pengobatan dan dukungan sosial serta psikologis kepada pasien untuk menbantu pasien tetap konsisten menjalani pengobatan.
DKI Jakarta Province is one of 4 Provinces in Indonesia for the initial implementation site of the BPaL (Bedaquiline, Pretomanid, Linezolid) combination for treating DR-TB (Drug Resistant Tuberculosis) in an operational research order. The study aimed to compare the success of treatment of TB RO patients with the use of Bedaquiline in the treatment combination with the success of treatment of TB RO patients without Bedaquiline in the treatment combination. The study used a retrospective cohort design and data analysis with survival analysis from the Tuberculosis Information System (SITB) data of DKI Jakarta Province in 2020 – 2023. Results of the study shows that in Monoresistant, Rifampicin Resistant, Polyresistant and Multidrugs Resistant resistance patterns, the success of treatment combination using Bedaquiline did not show a significant difference with the success of treatment combination without using Bedaquiline after being controlled by treatment combination type variable (HR 1.01; 95% CI 0.79 -1.29; p-value = 0.939). In pre-Extensively Drug Resistant and Extensively Drug Resistant resistance patterns, the success of treatment combination using Bedaquiline was also not significantly different when compared to the success of the treatment combination without Bedaquiline after being controlled by treatment combination type variable (HR 1.14; 95% CI 0.34 – 3.82; p-value = 0.835). Health workers are expected to continue providing education on the importance of compliance with treatment regimens and giving social and psychological support to patients in order to maintain patient’s consistency in undergoing treatment.
